| Clinical Summaries
The efficacy of MigraSpray was demonstrated in a recent randomized, placebo-controlled, double-blind, crossover trial for migraine headache relief drawn from a general population, reporting migraine headaches. The strength of this trial includes its draw from a general population, design, outside review, extremely high safety record, equal baseline characteristics between the two groups (placebo and product), and statistical significance in all the major end-point categories. The results of the trial demonstrated that nearly eighty-eight percent of the patients studied using MigraSpray received some degree of relief from their migraine headache symptoms within an average of fewer than 7 minutes. The results of this study are statistically significant, at a P value of less than 0.01 in all parameters.
Click to read through Executive Summary
Moreover, an ongoing study testing the efficacy of using MigraSpray for prophylaxis is being conducted in New York City by Dr. Fred Pescatore, M.D., MPH, Director of the Centers for Integrative and Complimentary Medicine in New York City and Dallas. Of the patients studied using MigraSpray on a continual daily basis, approximately 90% have had their migraine headache attacks eliminated.
Feverfew | Summary & Clinical Data
The herb Feverfew (Pyrethrum Parthenium), also known as Tanacetum parthenium, is native to Europe, although it is now commonly found in many parts of the world, including North and South America. Feverfew is a perennial plant and is classified as a member of the Asteracea or Compositea family, a relative of the daisy.
The active ingredients in Feverfew are sesquiterpene lactones, the primary component being parthenolide, a phyto-chemical. Studies have shown that parthenolide inhibits platelet aggregation and the release of serotonin from platelets. Feverfew has also been shown to inhibit pro-inflammatory prostaglandin synthesis. These anti-inflammatory properties may control the inflammation that results in cerebral blood vessel dilation, a cause or contributor to the symptoms of migraine headaches.
Feverfew has been used for centuries and originally became popular with English herbalists in the middle ages. As the name suggests, feverfew was used as an application for the treatment of fevers. However, the word fever at that time referred to a number of ailments, including rheumatic aches, abdominal pain and headaches.
Over the past two decades medical interest of feverfew has been rekindled in response to various in-vitro studies as well as the wide spread use of feverfew among the general public. A number of research groups have formally investigated the clinical use of the herb for the relief of symptoms of migraine headaches.
Several studies, including one in The Lancet and another in The British Medical Journal have demonstrated feverfews potential for migraine relief. These double blind placebo studies showed a statistically significant number of patients reporting a reduction in the number and/or severity of migraine attacks.
Subsequent studies have substantiated the use of feverfew in controlling the symptoms of migraines.